Retinoic acid receptor γ is a therapeutically targetable driver of growth and survival in prostate cancer

Abstract

We suggest that the use of RARγ-selective antagonists may be effective in PC (and potentially other cancers), either as a single agent or in combination with cytotoxic chemotherapy.